These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23687785)

  • 41. An overview of HER-targeted therapy with lapatinib in breast cancer.
    McArthur H
    Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient.
    Freedman RA; Muss HB
    J Geriatr Oncol; 2014 Jan; 5(1):2-7. PubMed ID: 24484711
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systemic treatment of HER2-positive metastatic breast cancer: a systematic review.
    Wilcken N; Zdenkowski N; White M; Snyder R; Pittman K; Mainwaring P; Green M; Francis P; De Boer R; Colosimo M; Chua S; Chirgwin J; Beith J; Bell R
    Asia Pac J Clin Oncol; 2014 Jun; 10 Suppl S4():1-14. PubMed ID: 24797445
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neoadjuvant and Adjuvant Therapy for HER2 Positive Disease.
    Chia SK
    Am Soc Clin Oncol Educ Book; 2015; ():e41-8. PubMed ID: 25993203
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all?
    Miglietta F; Dieci MV; Griguolo G; Guarneri V; Conte PF
    Cancer Treat Rev; 2017 Nov; 60():100-108. PubMed ID: 28942029
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HER2 as a cancer stem-cell target.
    Roesler R; Cornelio DB; Abujamra AL; Schwartsmann G
    Lancet Oncol; 2010 Mar; 11(3):225-6. PubMed ID: 20202610
    [No Abstract]   [Full Text] [Related]  

  • 47. [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
    Ismaili N; Belbaraka R; Elomrani A; Khouchani M; Tahri A
    Presse Med; 2013 Nov; 42(11):1461-8. PubMed ID: 23721860
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biological considerations and clinical applications of new HER2-targeted agents.
    Higa GM; Singh V; Abraham J
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1497-509. PubMed ID: 20836684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM; Boster BL; Barnett CM
    J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The immune system and response to HER2-targeted treatment in breast cancer.
    Bianchini G; Gianni L
    Lancet Oncol; 2014 Feb; 15(2):e58-68. PubMed ID: 24480556
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting alternative pathways in HER2-positive breast cancer.
    Rastogi P
    Oncology (Williston Park); 2010 Apr; 24(5):415-6. PubMed ID: 20480739
    [No Abstract]   [Full Text] [Related]  

  • 52. HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials.
    Dent S; Oyan B; Honig A; Mano M; Howell S
    Cancer Treat Rev; 2013 Oct; 39(6):622-31. PubMed ID: 23434074
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy.
    Ellis MJ
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139535
    [No Abstract]   [Full Text] [Related]  

  • 54. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HER2-positive breast cancer: beyond trastuzumab.
    Murphy CG; Fornier M
    Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.
    Creedon H; Byron A; Main J; Hayward L; Klinowska T; Brunton VG
    Biochem Soc Trans; 2014 Aug; 42(4):822-30. PubMed ID: 25109964
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.
    Ibrahim EM; Kazkaz GA; Al-Mansour MM; Al-Foheidi ME
    Breast Cancer Res Treat; 2015 Aug; 152(3):463-76. PubMed ID: 26105797
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
    Glück S; Arteaga CL; Osborne CK
    Clin Cancer Res; 2011 Sep; 17(17):5559-61. PubMed ID: 21764887
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanisms of resistance to HER2 target therapy.
    Tortora G
    J Natl Cancer Inst Monogr; 2011; 2011(43):95-8. PubMed ID: 22043051
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
    Tokuda Y; Suzuki Y; Saito Y; Umemura S
    Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.